<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">ESTROGENS, CONJUGATED</span><br/>(ess'tro-jenz)<br/><span class="topboxtradename">C.E.S. <img border="0" src="../images/maple.gif"/>, </span><span class="topboxtradename">Cenestin, </span><span class="topboxtradename">Enjuvia, </span><span class="topboxtradename">Premarin, </span><span class="topboxtradename">Progens<br/></span><b>Classifications:</b> <span class="classification">hormones &amp; synthetic substitutes</span>; <span class="classification">estrogens</span><br/><b>Prototype: </b>Estradiol<br/><b>Pregnancy Category: </b>X<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>0.3 mg, 0.45 mg, 0.625 mg, 0.9 mg, 1.25 mg, 2.5 mg tablets; 25 mg injection; 0.625 mg vaginal cream</p>
<h1><a name="action">Actions</a></h1>
<p>Short-acting estrogen mixture of conjugated estrogens including sodium estrone sulfate and sodium equilin sulfate.</p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>Binds to intracellular receptors that stimulate DNA and RNA to synthesize proteins responsible for effects of estrogen.</p>
<h1><a name="uses">Uses</a></h1>
<p>Atrophic vaginitis, kraurosis vulvae, and abnormal bleeding (hormonal imbalance); also female hypogonadism, primary ovarian
         failure, vasomotor symptoms associated with menopause; to retard progression of osteoporosis and as palliative therapy of
         breast and prostatic carcinomas.
      </p>
<h1><a name="unlabeleduses">Unlabeled Uses</a></h1>
<p>Postcoital contraceptive.</p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Breast cancer; known or suspected pregnancy (category X), lactation.</p>
<h1><a name="precaution">Cautious Use</a></h1>
<p>Hypertension; gallbladder disease; diabetes mellitus; heart failure; liver or kidney dysfunction, history of thromboembolic
         disease.
      </p>
<h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Menopause, Osteoporosis, Atrophic Vaginitis, Kraurosis Vulvae</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> 0.31.25 mg/d for 21 d each month, adjust to lowest level that gives symptom control (<img src="../images/special/lesserorequal.gif"/>0.625
               mg/d) <span class="rdroute">IV/IM</span> 25 mg, repeated in 612 h if needed <span class="rdroute">Topical</span> 24 g of cream/d<br/><br/><span class="indicationtitle">Female Hypogonadism</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> 2.57.5 mg/d in 13 divided doses for 20 d, followed by a 10 d rest period<br/><br/><span class="indicationtitle">Postcoital Contraception</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> 30 mg/d in divided doses for 5 consecutive days beginning within 72 h of coitus<br/><br/><span class="indicationtitle">Breast Cancer</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> 10 mg t.i.d. for at least 3 mo<br/><br/><span class="indicationtitle">Prostatic Cancer Palliation</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> 1.252.5 mg t.i.d.<br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1><span class="adminroutetype">Oral</span><br/><ul>
<li>Give cyclically except when used for treatment of postpartum breast engorgement and for palliation of cancer. Cyclic regimen
            is to dose for 3 wk followed by 1 wk off.
         </li>
</ul><span class="adminroutetype">Topical</span><br/><ul>
<li>Use calibrated dosage applicator dispensed with the cream.</li>
</ul><span class="adminroutetype">Intramuscular</span><br/><ul>
<li>Reconstitute by first removing approximately 5 mL of air from the dry-powder vial, then slowly inject the supplied diluent
            to the vial by aiming it at the side of the vial. Gently agitate to dissolve but <small>DO NOT SHAKE</small>.
         </li>
<li>Use within a few hours of reconstitution.</li>
</ul>
<table cellpadding="4" cellspacing="0" class="ivbox" width="100%">
<tr>
<td><span class="ivtitle">Intravenous</span><p><span class="routemethod">PREPARE:</span> <span class="methodtype">Direct:</span> Reconstitute as for IM injection.  
               </p>
<p><span class="routemethod">ADMINISTER:</span> <span class="methodtype">Direct:</span> Give slowly at a rate of 5 mg/min. Estrogen solution is compatible with D5W and NS and may be added to IV tubing just distal
                  to the needle if necessary.  
               </p>
</td>
</tr>
</table>
<ul>
<li>Store ampule and reconstituted solution at 2°8° C (38°46° F) and protected from light; stable
            for 60 d. Discard precipitated or discolored solution.
         </li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead">CNS:</span> Headache, dizziness, depression, <span class="speceff-common">libido changes.</span> <span class="typehead">CV:</span> <span class="speceff-life">Thromboembolic disorders</span>, hypertension. <span class="typehead">GI:</span> <span class="speceff-common">Nausea,</span> vomiting, diarrhea, bloating, cholestatic jaundice. <span class="typehead">Urogenital:</span> Mastodynia, spotting, changes in menstrual flow, dysmenorrhea, amenorrhea. <span class="typehead">Metabolic:</span> Reduced carbohydrate tolerance, fluid retention. <span class="typehead">Other:</span> Leg cramps, intolerance to contact lenses. 
      <h1><a name="interactions">Interactions</a></h1><span class="typehead">Drug:</span> <span class="classification">barbiturates</span>, <b>carbamazepine,</b> <b>phenytoin,</b> <b>rifampin</b> decrease estrogen effect by increasing its metabolism; <span class="classification">oral anticoagulants</span> may decrease hypoprothrombinemic effects; interfere with effects of <b>bromocriptine;</b> may increase levels and toxicity of <b>cyclosporine,</b> <span class="classification">tricyclic antidepressants</span>, <b>theophylline;</b> decrease effectiveness of <b>clofibrate.</b>
<h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Absorption:</span> Rapid absorption from GI tract; readily absorbed through skin and mucous membranes (including vaginal mucosa); slow absorption
      from IM injections. <span class="typehead">Distribution:</span> Distributed throughout body tissues, especially in adipose tissue; crosses placenta, excreted in breast milk. Conjugated estrogens
      are bound primarily to albumin. <span class="typehead">Metabolism:</span> Metabolized primarily in liver to glucuronide and sulfate conjugates of estradiol, estrone, and estriol. <span class="typehead">Elimination:</span> Excreted in urine. <span class="typehead">Half-Life:</span> 418 h. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>See additional implications under estradiol.</li>
<li>Monitor for and report breakthrough vaginal bleeding.</li>
<li>Assess for relief of menopausal symptoms.</li>
<li>Lab tests: Monitor serum phosphatase levels with prostate cancer.</li>
<li>Monitor bone density annually when used for osteoporosis prophylaxis.</li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>Be aware of importance of taking drug exactly as prescribed: Specifically, do not omit, increase, or decrease doses without
            advice of physician.
         </li>
<li>Intravaginal administration: For self-administration, wash hands well before and after application, and avoid contact of denuded
            areas with the cream. Do not use tampons while on vaginal cream therapy.
         </li>
<li>Notify physician promptly of adverse symptoms.</li>
<li>Risk of blood clot formation is high with morning after pill. Know signs of thrombophlebitis (see Appendix F).</li>
<li>Review package insert to ensure understanding of estrogen therapy.</li>
<li>Do not breast feed while taking this drug.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>